Silence Therapeutics PLC Issue of claim in the UK High Courts (9271J)
July 03 2017 - 8:34AM
UK Regulatory
TIDMSLN
RNS Number : 9271J
Silence Therapeutics PLC
03 July 2017
Issue of claim in the UK High Courts
3 July 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that it has today issued a claim in the UK
High Courts of Justice (Patents Court) naming as defendants Alnylam
UK Limited, Alnylam Pharmaceuticals Inc, and The Medicines Company
UK Limited.
Silence has previously stated that it is committed to defending
its Intellectual Property (IP) and to secure the appropriate value
for this IP, it will act to enforce its patent estate as necessary.
The claim asks the Court to determine whether Silence is entitled
to "supplementary protection certificates" (SPCs) on several late
stage Alnylam products, which include Patisiran, Fitusiran,
Givosiran and Inclisiran (partnered with The Medicines Company),
and could result in the extension of Silence's European patent
protection on these products. SPCs are intellectual property rights
which can give up to 5 years of exclusivity after a patent expires.
Separately, Silence is actively continuing to uphold its patent
estate in other global regions.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"We reiterate, as stated in our press release on 30th May 2017,
that we consider potential licences under our patent estate could
have a significant financial effect relative to the current market
capitalisation of Silence. As such, we consider the commencement of
this process to be the next step in realising this value."
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0) 20
FTI Consulting 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBGGDRLDGBGRX
(END) Dow Jones Newswires
July 03, 2017 09:34 ET (13:34 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024